TheraRadar
Data updated: May 26, 2026

DESOWEN (desonide)

Corticosteroid Hormone Receptor Agonists
Dermatology Approved 1984-12-14

DESOWEN is indicated for the treatment of Dermatoses.

Source: FDA Label • GALDERMA LABS LP
Jump to: Indications Approvals Trials Competitors Similar Safety Patents
3
Indications
--
Phase 3 Trials
41
Years on Market

Details

Status
Discontinued
First Approved
1984-12-14
Routes
TOPICAL
Dosage Forms
OINTMENT, LOTION, CREAM

Companies

GALDERMA LABS LP
Active Ingredient: DESONIDE

DESOWEN Approval History

1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
28 FDA actions from 1984 to 2015
Apr 2015 SUPPL
Label · Labeling
Mar 2013 SUPPL
Mfg · Manufacturing (CMC)
Jun 1998 SUPPL
Label · Labeling

What DESOWEN Treats

1 indications

DESOWEN is approved for 1 conditions since its original approval in 1984. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Dermatoses
Source: FDA Label

DESOWEN Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Indication competitors

10

Same indication, different mechanism — what else might this patient receive?

HALOBETASOL PROPIONATE AND TAZAROTENE
SUN PHARMA
2025 1 indic.
CLOCORTOLONE PIVALATE
TARO
2020 1 indic.
Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to DESOWEN

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ALA-SCALP
HYDROCORTISONE
1 shared
LEGACY PHARMA
Shared indications:
Dermatoses
ALCLOMETASONE DIPROPIONATE
ALCLOMETASONE DIPROPIONATE
1 shared
SUN PHARMA CANADA
Shared indications:
Dermatoses
AMCINONIDE
AMCINONIDE
1 shared
TARO PHARM INDS
Shared indications:
Dermatoses
View all 20 similar drugs Pro
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT02624544 EMS Ph 4 withdrawn Proton Pump Inhibitors Use in Patients With Psoriasis
NCT01542138 NIADESAH Ph 4 completed Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DESOWEN FDA Label Details

Indications & Usage

DESOWEN is indicated for the treatment of Dermatoses.

Track DESOWEN with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

FDA Approval: ANDA071425 → Label: DailyMed → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.